Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aptose Biosciences, Inc.

< Previous 1 2 Next >
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Present at the Cantor Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Second Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Presents Highlights from Clinical Update
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Provides Update on Reverse Stock Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Enters into $25 Million Committed Equity Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the First Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Fourth Quarter and Full Year 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.